A phase III clinical trial of rapid-dissolving fluoxetine in a subpopulation of patients with autistic disorder.

Trial Profile

A phase III clinical trial of rapid-dissolving fluoxetine in a subpopulation of patients with autistic disorder.

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2012

At a glance

  • Drugs Fluoxetine (Primary)
  • Indications Autistic disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Oct 2012 Autism Therapeutics has had a Type C Guidance Meeting with the US FDA to discuss the completion of a phase III programme for fluoxetine rapid dissolve under Special Protocol Assessment (SPA) guidelines, according to an Autism Therapeutics media release.
    • 02 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top